Ask AI
2025 SABCS MBC

CME

Decera Clinical Education Independent Conference Highlights of the San Antonio Breast Cancer Symposium 2025: Advanced and Metastatic Breast Cancer

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: February 20, 2026

Expiration: August 19, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Erica L. Mayer, MD, MPH, FASCO, and Sara M. Tolaney, MD, MPH, discuss key studies in advanced and metastatic breast cancer (MBC) that were presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), with a focus on new research of interest and clinical trial updates.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary. 

Please note that Decera Clinical Education plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with breast cancer do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

According to results presented at SABCS 2025 from a pooled analysis of the phase III MONALEESA trials, what information about disease characteristics associated with long‑term response (LTR) or very long–term response (VLTR) to ribociclib plus a nonsteroidal aromatase inhibitor (AI) would you discuss with a patient considering this regimen as first‑line therapy?

How confident are you in your answer?

Based on the phase II ELEVATE trial results presented at SABCS 2025, which agent combined with elacestrant produced a median progression-free survival (PFS) of more than 12 months in previously treated patients with ABC who had received 1-2 prior lines of ET with or without a CDK4/6 inhibitor?

How confident are you in your answer?

The phase III EMBER 3 trial enrolled patients with ER-positive/HER2-negative advanced or metastatic breast cancer whose disease progressed during or after AI therapy with or without prior CDK4/6 inhibitor exposure. Which of the following statements best reflects the benefit in median PFS with imlunestrant plus abemaciclib vs imlunestrant alone across various patient subgroups in this trial, as reported at SABCS 2025?

How confident are you in your answer?